ID   3C5 [Mouse hybridoma against human PSCA]
AC   CVCL_B0TR
DR   Wikidata; Q108819587
RX   Patent=US8524460;
RX   PubMed=10713670;
RX   PubMed=11226295;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12616.
CC   Monoclonal antibody isotype: IgG2a, kappa.
CC   Monoclonal antibody target: UniProtKB; O43653; Human PSCA.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_D145 ! HL-1 Friendly Myeloma-653
CA   Hybridoma
DT   Created: 23-09-21; Last updated: 21-03-23; Version: 3
//
RX   Patent=US8524460;
RA   Reiter R.E., Witte O.N.;
RT   "PSCA: prostate stem cell antigen and uses thereof.";
RL   Patent number US8524460, 03-Sep-2013.
//
RX   PubMed=10713670; DOI=10.1038/sj.onc.1203426;
RA   Gu Z., Thomas G., Yamashiro J., Shintaku I.P., Dorey F., Raitano A.B.,
RA   Witte O.N., Said J.W., Loda M., Reiter R.E.;
RT   "Prostate stem cell antigen (PSCA) expression increases with high
RT   Gleason score, advanced stage and bone metastasis in prostate
RT   cancer.";
RL   Oncogene 19:1288-1296(2000).
//
RX   PubMed=11226295; DOI=10.1073/pnas.051624698;
RA   Saffran D.C., Raitano A.B., Hubert R.S., Witte O.N., Reiter R.E.,
RA   Jakobovits A.;
RT   "Anti-PSCA mAbs inhibit tumor growth and metastasis formation and
RT   prolong the survival of mice bearing human prostate cancer
RT   xenografts.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2658-2663(2001).
//